Literature DB >> 24803633

Clinically relevant pharmacogenomic testing in pediatric practice.

Lindsey Korbel1, Mathew George2, Joseph Kitzmiller3.   

Abstract

Clinicians and patients continue to convey interest in personalized medicine. The objective of personalized medicine is to improve healthcare by tailoring disease prevention, diagnosis, and treatment strategies for individuals based on their unique clinical history and genetic composition. This article offers an overview of pharmacogenomics, discusses caveats specific to pharmacogenomics in pediatric populations, provides evidence-based recommendations for pediatric clinicians, and offers insight regarding the future role of pharmacogenomics testing in pediatric medicine. Reviews of the current literature and thoughtful discussions are presented regarding the pharmacogenomics of antidepressants, codeine and oncologic, asthma, and immunomodulatory pharmacotherapies.
© The Author(s) 2014.

Entities:  

Keywords:  genetics; pediatrics; pharmacogenomics; pharmacotherapy

Mesh：

Substances：

Year:  2014        PMID： 24803633      PMCID： PMC4222996          DOI： 10.1177/0009922814533186

Source DB:  PubMed          Journal:  Clin Pediatr (Phila)        ISSN： 0009-9228            Impact factor:   1.168


  21 in total

1.  Variation at GLCCI1 and FCER2: one step closer to personalized asthma treatment.

Authors:  Anke Hilse Maitland-van der Zee; Jan Am Raaijmakers
Journal:  Pharmacogenomics       Date:  2012-02       Impact factor: 2.533

Review 2.  Pharmacogenomics in pediatric leukemia.

Authors:  Steven W Paugh; Gabriele Stocco; William E Evans
Journal:  Curr Opin Pediatr       Date:  2010-12       Impact factor: 2.856

Review 3.  Psychiatric pharmacogenomics in pediatric psychopharmacology.

Authors:  Christopher A Wall; Paul E Croarkin; Cosima Swintak; Brett A Koplin
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2012-10

Review 4.  Pharmacogenomics in pediatric rheumatology.

Authors:  Mara L Becker
Journal:  Curr Opin Rheumatol       Date:  2012-09       Impact factor: 5.006

5.  Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines.

Authors:  Laure Elens; Arnaud Capron; Ron H N van Schaik; Martine De Meyer; Luc De Pauw; Djamila C Eddour; Dominique Latinne; Pierre Wallemacq; Michel Mourad; Vincent Haufroid
Journal:  Ther Drug Monit       Date:  2013-10       Impact factor: 3.681

Review 6.  Personalized medicine in pediatric cardiology: do little changes make a big difference?

Authors:  Ashok K Manickaraj; Seema Mital
Journal:  Curr Opin Pediatr       Date:  2012-10       Impact factor: 2.856

7.  Immunosuppression therapy for pediatric heart transplantation.

Authors:  Claire A Irving; Steven A Webber
Journal:  Curr Treat Options Cardiovasc Med       Date:  2010-10

Review 8.  Treatment heterogeneity in asthma: genetics of response to leukotriene modifiers.

Authors:  John J Lima
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

9.  Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline.

Authors:  Peter R Joyce; Roger T Mulder; Suzanne E Luty; Janice M McKenzie; Allison L Miller; Geraldine R Rogers; Martin A Kennedy
Journal:  Int J Neuropsychopharmacol       Date:  2003-12       Impact factor: 5.176

Review 10.  A systematic review and meta-analysis of MTHFR polymorphisms in methotrexate toxicity prediction in pediatric acute lymphoblastic leukemia.

Authors:  E Lopez-Lopez; I Martin-Guerrero; J Ballesteros; A Garcia-Orad
Journal:  Pharmacogenomics J       Date:  2012-10-23       Impact factor: 3.550
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.